The Bi-steric Inhibitor RMC-5552 Reduces mTORC1 Signaling and Growth in Lymphangioleiomyomatosis
Jilly F. Evans(Merck & Co., Inc., Rahway, NJ, USA (United States)), Vera P. Krymskaya(University of Pennsylvania), Yan Tang(Brigham and Women's Hospital), Edward Cantu(Hospital of the University of Pennsylvania), Rémi Diesler(Université Claude Bernard Lyon 1), Maria C. Basil(Boston University), Elizabeth P. Henske(Brigham and Women's Hospital), Susan M. Lin(Hospital of the University of Pennsylvania), Alexander R. Mukhitov(University of Pennsylvania), O. Ledwell(Pulmonary and Allergy Associates), Ryan W. Rue(University of Pennsylvania)
Cited by 7
Related Papers
Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)
|Cell|1996|2.4k
The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma
|Cancer Cell|2014|860
Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
|Nature reviews. Immunology|2015|758
Clinical Risk Factors for Primary Graft Dysfunction after Lung Transplantation
|American Journal of Respiratory and Critical Care Medicine|2013|686